STARTING JAN. 1, 2017, there are substantial penalties for labs that fail to properly meet the complex lab test price marketing reporting requirements of the Protecting Access to Medicare Act of 2014. Labs that fail to do so face the potential of stiff, multi-million dollar fines. “Under PAMA, clinical labs need to report full and …
PAMA Reporting Penalties Can Be Substantial for Laboratories Read More »
To access this post, you must purchase The Dark Report.